---
type: source
title: "Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes"
author: "Multiple Authors (PMC12694361)"
url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12694361/
date: 2025-10-01
domain: health
secondary_domains: []
format: article
status: unprocessed
priority: high
tags: [glp-1, eating-disorders, systematic-review, binge-eating, bulimia, anorexia, screening, behavioral-health, co-treatment]
intake_tier: research-task
---

## Content

Systematic review on GLP-1 receptor agonists and appetite regulation in eating disorder context. Published as MDPI Nutrients (2025).

**Main argument:** GLP-1RAs are at "the intersection of medical innovation and psychological risk." Require integrated psychological monitoring within multidisciplinary care.

**Evidence on new-onset EDs:** "To date, no clinical evidence links GLP-1RA use to the onset or worsening of AN." Strong statement. Theoretical concerns exist but no causal evidence.

**GI side effects and purging:** "Gastrointestinal symptoms such as nausea and vomiting may complicate treatment, particularly in patients with purging behaviours, where these side effects could inadvertently reinforce or exacerbate *existing* cycles." — the qualifier is "existing cycles," not new onset.

**Vulnerability markers identified (not confirmed risk factors):**
- High perfectionism and obsessive-compulsive traits
- Elevated baseline emotional eating
- Mixed binge-purge + restrictive patterns
- Weight suppression history

**Pre-treatment screening recommendations:**
- SCOFF questionnaire administration
- Recent ED history review
- Assessment for compensatory behaviors
- Weight-suppression history evaluation

**Red flags during treatment:**
- Rapid weight loss
- Dizziness/syncope
- Escalating restriction
- Purging or laxative use

**Evidence quality assessment:** Low-to-moderate confidence throughout. BED/BN findings "preliminary." Restrictive ED evidence "scarce and inconclusive." "Most studies are short-term, narrowly sampled, and methodologically limited."

## Agent Notes

**Why this matters:** This is the most comprehensive current review on the GLP-1 + ED risk question. The explicit "no clinical evidence links GLP-1RA to onset or worsening of AN" statement is the strongest summary of the current evidence state for the primary disconfirmation question.

**What surprised me:** How definitively the review frames the absence of evidence for de novo AN. This is not "evidence of absence" framing — this is "the mechanism requires pre-existing vulnerability, and we have no evidence of pharmacological causation."

**What I expected but didn't find:** Long-term follow-up data (>1 year). The review explicitly identifies this as missing: "most studies are short-term."

**KB connections:** [[human-in-the-loop clinical AI degrades to worse-than-AI-alone]] — parallel structural point about how well-intentioned interventions can harm vulnerable populations when proper screening/safeguards aren't in place.

**Extraction hints:** (1) "No clinical evidence links GLP-1RA use to onset or worsening of AN" — this is the strongest current statement closing the de novo causation question, (2) Screening protocol (SCOFF + history + behavioral assessment) as a clinical governance recommendation, (3) GI effects reinforce EXISTING purging cycles, not create new ones.

**Context:** October 2025 systematic review, MDPI Nutrients (peer-reviewed).

## Curator Notes

PRIMARY CONNECTION: [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]

WHY ARCHIVED: This review provides the most authoritative current evidence synthesis for the GLP-1 de novo ED question. The "no clinical evidence for onset" statement + "GI effects exacerbate existing cycles" together close the session 36 disconfirmation hypothesis — behavioral substrate is necessary.

EXTRACTION HINT: This source closes the GI-mediated purging disconfirmation hypothesis definitively enough to write a claim: "GLP-1-induced GI side effects may reinforce pre-existing purging cycles but no clinical evidence supports de novo eating disorder induction in patients without behavioral vulnerability." Scope carefully — 'experimental' confidence given limited RCT evidence.